Gemifloxacin

Garenoxacin, gatifloxacin, and gemifloxacin were highlighted in a 2004 study for their superior activity against resistant strains of Mycoplasma and Ureaplasma compared to traditional quinolones like ciprofloxacin and levofloxacin. Gemifloxacin was particularly effective, with MICs of ≤1 μg/ml even in strains with mutations, showcasing its strength against respiratory pathogens. Further studies supported its efficacy; a 2005 test on H. influenzae strains demonstrated that gemifloxacin maintained activity irrespective of β-lactam or macrolide resistance. Similarly, in a Saudi Arabian study, gemifloxacin exhibited complete susceptibility against S. pneumoniae, H. influenzae, and M. catarrhalis, outperforming some other quinolones in activity. Importantly, no bacterial isolates tested displayed resistance to gemifloxacin, highlighting its reliability in treating challenging infections like acute bacterial exacerbations of chronic bronchitis (AECB).

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.